Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis C

Free Subscription Articles published in J Med Virol Retrieve available abstracts of 34 articles: HTML format

Single Articles

September 2023
1. PENG X, Shi Y, Zhang B, Xu C, et al
   Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
   J Med Virol. 2023;95:e29084.
   PubMed     Abstract available
   
   
   
2. LIU C, Guo M, Han L, Lu J, et al
   Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
   J Med Virol. 2023;95:e29103.
   PubMed     Abstract available
   
   
   August 2023
3. ADACHI E, Saito M, Kikuchi T, Ikeuchi K, et al
   Incidence of sexually transmitted hepatitis C virus infection among men who have sex with men in Japan from 2009 to 2023.
   J Med Virol. 2023;95:e29039.
   PubMed     Abstract available
   
   
   July 2023
4. LARA-AGUILAR V, Crespo-Bermejo C, Llamas-Adan M, Grande-Garcia S, et al
   HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART.
   J Med Virol. 2023;95:e28955.
   PubMed     Abstract available
   
   
   
5. QU Y, Wang W, Xiao MZX, Zheng Y, et al
   The interplay between lipid droplets and virus infection.
   J Med Virol. 2023;95:e28967.
   PubMed     Abstract available
   
   
   March 2023
6. WU B, Tobe RG, Yan M, Lin H, et al
   Trends of Global Burden Related to HBV and HCV from 1990 to 2019: An Age-Period-Cohort Analysis.
   J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28663.
   PubMed     Abstract available
   
   
   
7. PISATURO M, Alessio L, Starace M, Macera M, et al
   CHARACTERIZATION OF HEPATITIS VIRUS CO-INFECTIONS IN A COHORT OF IMMIGRANTS LIVING IN SOUTHERN ITALY.
   J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28665.
   PubMed     Abstract available
   
   
   
8. FENG Z, Huang P, Zhang J, Xia X, et al
   KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.
   J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28645.
   PubMed     Abstract available
   
   
   February 2023
9. NOT A, Saludes V, Galvez M, Miralpeix A, et al
   Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
   J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
   PubMed     Abstract available
   
   
   January 2023
10. MOHAMED AA, Esmail OE, Ibrahim AMA, Makled S, et al
    The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients.
    J Med Virol. 2023;95:e28343.
    PubMed     Abstract available
    
    
    November 2022
11. ARANDHARA VL, Patrick McClure C, Tarr AW, Chappell S, et al
    SCAVENGER RECEPTOR CLASS B TYPE I GENETIC VARIANTS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC HEPATITIS C VIRUS INFECTION.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28331.
    PubMed     Abstract available
    
    
    September 2022
12. ADEBOYEJO K, King B, Tsoleridis T, Tarr A, et al
    Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28178.
    PubMed     Abstract available
    
    
    August 2022
13. PRICE AS, Nelson AK, Ghosh A, Kottilil S, et al
    A Phase 2 Open Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28105.
    PubMed     Abstract available
    
    
    July 2022
14. RUPASINGHE D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al
    Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28019.
    PubMed     Abstract available
    
    
    June 2022
15. OHTA A, Ogawa E, Murata M, Matsumoto Y, et al
    Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27904.
    PubMed     Abstract available
    
    
    May 2022
16. ZENG QL, Yu ZJ, Lv J, Zhang HX, et al
    Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27877.
    PubMed     Abstract available
    
    
    
17. XIE Z, Deng K, Xia Y, Zhang C, et al
    Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27851.
    PubMed     Abstract available
    
    
    
18. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    PubMed     Abstract available
    
    
    January 2022
19. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    PubMed     Abstract available
    
    
    November 2021
20. BOLINA-SANTOS E, Chaves DG, da Silva-Malta MCF, Carmo RA, et al
    HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27432.
    PubMed     Abstract available
    
    
    October 2021
21. JI Q, Chu X, Zhou Y, Liu X, et al
    Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    J Med Virol. 2021 Oct 2. doi: 10.1002/jmv.27374.
    PubMed     Abstract available
    
    
    September 2021
22. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    PubMed     Abstract available
    
    
    
23. NICOLINI LA, Menzaghi B, Molteni C, Vichi F, et al
    Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27329.
    PubMed    
    
    
    August 2021
24. ZHOU R, Liu L, Wang Y
    Viral Proteins Recognized by Different TLRs.
    J Med Virol. 2021 Aug 10. doi: 10.1002/jmv.27265.
    PubMed     Abstract available
    
    
    July 2021
25. WEI MT, Le MH, Landis C, Trinh H, et al
    Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27168.
    PubMed     Abstract available
    
    
    June 2021
26. LEUMI S, El Kassas M, Zhong J
    Hepatitis C virus-genotype 4: a poorly characterized endemic genotype.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27165.
    PubMed     Abstract available
    
    
    
27. TADA T, Kurosaki M, Nakamura S, Hasebe C, et al
    Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27157.
    PubMed     Abstract available
    
    
    April 2021
28. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    PubMed     Abstract available
    
    
    March 2021
29. ELHENCE A, Singh A, Anand A, Kumar R, et al
    Real-World Re-Treatment Outcomes of Direct-Acting Antiviral Therapy Failure in Patients with Chronic Hepatitis C.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26971.
    PubMed     Abstract available
    
    
    
30. FEDORCHENKO SV, Martynovych T, Klimenko Z, Solianyk I, et al
    Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin in patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous with first- and second-generation NS5A inhibitors.
    J Med Virol. 2021 Mar 11. doi: 10.1002/jmv.26935.
    PubMed     Abstract available
    
    
    December 2020
31. MIRANDA NTGP, de Souza RL, Monteiro JC, Costa IB, et al
    Seroprevalence of HBV and HCV in female sex workers from four cities in the state of Para, northern Brazil.
    J Med Virol. 2020 Dec 25. doi: 10.1002/jmv.26759.
    PubMed     Abstract available
    
    
    November 2020
32. CHUA JV, Ntem-Mensah A, Abutaleb A, Husson J, et al
    Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: an open-label study.
    J Med Virol. 2020 Nov 5. doi: 10.1002/jmv.26652.
    PubMed     Abstract available
    
    
    December 2019
33. KIM M, Kyung Lee Y, Park B, Jun Oh D, et al
    Hepatitis virus B and C infections are associated with an increased risk of non-Hodgkin lymphoma: A nested case-control study using a national sample cohort.
    J Med Virol. 2019 Dec 11. doi: 10.1002/jmv.25653.
    PubMed     Abstract available
    
    
    April 2019
34. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: